Needham analyst Joseph Stringer has maintained their neutral stance on MRNA stock, giving a Hold rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Stringer has given his Hold rating due to a combination of factors affecting Moderna’s current and future performance. Despite reporting second-quarter revenue that exceeded expectations, Moderna’s revenue guidance for 2025 has been adjusted downward, reflecting challenges in shipment timing. This adjustment indicates potential volatility in revenue streams, which contributes to a cautious outlook.
Additionally, Moderna’s focus on cost-cutting measures, such as a reduction in workforce, underscores the pressure on its financials due to declining COVID vaccine revenues. While the company’s vaccine franchise faces headwinds, and the rare disease pipeline remains promising but not yet impactful, the oncology pipeline is seen as having significant potential. However, major developments in this area are not anticipated until 2026 or later, prompting a Hold rating as the company navigates these challenges and opportunities.
According to TipRanks, Stringer is a 4-star analyst with an average return of 5.8% and a 42.05% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Cidara Therapeutics, Gilead Sciences, and Vir Biotechnology.
In another report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $29.00 price target.